| 52.13 2.22 (4.45%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.47 |
1-year : | 81.14 |
| Resists | First : | 59.47 |
Second : | 69.47 |
| Pivot price | 48.14 |
|||
| Supports | First : | 49.85 |
Second : | 43.9 |
| MAs | MA(5) : | 49.08 |
MA(20) : | 47.91 |
| MA(100) : | 49.34 |
MA(250) : | 36.75 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 62.7 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 59.54 | Low : | 22.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MRNA ] has closed Bollinger Bands are 32.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 52.29 - 52.49 | 52.49 - 52.69 |
| Low: | 49.32 - 49.56 | 49.56 - 49.8 |
| Close: | 51.74 - 52.11 | 52.11 - 52.48 |
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Mon, 15 Jun 2026
Moderna (NASDAQ: MRNA) insider sale: 53,336 shares via option exercise - Stock Titan
Mon, 15 Jun 2026
Wittenberg Investment Management Inc. Invests $988,000 in Moderna, Inc. $MRNA - MarketBeat
Mon, 15 Jun 2026
Fieldview Capital Management LLC Buys Shares of 58,752 Moderna, Inc. $MRNA - MarketBeat
Sat, 13 Jun 2026
Y Intercept Hong Kong Ltd Invests $13.59 Million in Moderna, Inc. $MRNA - MarketBeat
Tue, 09 Jun 2026
Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome - BioWorld News
Thu, 04 Jun 2026
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Barchart.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 397 (M) |
| Shares Float | 370 (M) |
| Held by Insiders | 7.3 (%) |
| Held by Institutions | 78.9 (%) |
| Shares Short | 57,810 (K) |
| Shares Short P.Month | 58,310 (K) |
| EPS | -8.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.65 |
| Profit Margin | -143.6 % |
| Operating Margin | -131.2 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -36.6 % |
| Qtrly Rev. Growth | 260.2 % |
| Gross Profit (p.s.) | -3.94 |
| Sales Per Share | 5.59 |
| EBITDA (p.s.) | -5.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,470 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -6.41 |
| PEG Ratio | 0 |
| Price to Book value | 2.79 |
| Price to Sales | 9.31 |
| Price to Cash Flow | -14.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|